These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. Rosenberg R, Baladi M, Bron M. J Clin Sleep Med; 2021 Apr 01; 17(4):711-717. PubMed ID: 33226332 [Abstract] [Full Text] [Related]
8. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Subedi R, Singh R, Thakur RK, K C B, Jha D, Ray BK. Sleep Med; 2020 Nov 01; 75():510-521. PubMed ID: 33032062 [Abstract] [Full Text] [Related]
9. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy. Thorpy MJ, Hyman D, Parks GS, Chen A, Foley C, Baldys B, Ito D, Singh H. Clin Ther; 2022 Oct 01; 44(10):1356-1369. PubMed ID: 36171171 [Abstract] [Full Text] [Related]
10. Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea. Powell J, Piszczatoski C, Garland S. Ann Pharmacother; 2020 Oct 01; 54(10):1016-1020. PubMed ID: 32270686 [Abstract] [Full Text] [Related]
11. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G. Sleep Med; 2021 Mar 01; 79():40-47. PubMed ID: 33472129 [Abstract] [Full Text] [Related]
14. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP, TONES 3 Study Investigators. Am J Respir Crit Care Med; 2019 Jun 01; 199(11):1421-1431. PubMed ID: 30521757 [Abstract] [Full Text] [Related]
17. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A. J Clin Sleep Med; 2021 Apr 01; 17(4):659-668. PubMed ID: 33179591 [Abstract] [Full Text] [Related]
18. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA. Mov Disord; 2021 Oct 01; 36(10):2408-2412. PubMed ID: 34191352 [Abstract] [Full Text] [Related]
19. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. Strollo PJ, Hedner J, Collop N, Lorch DG, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S, Tones 4 Study Investigators. Chest; 2019 Feb 01; 155(2):364-374. PubMed ID: 30471270 [Abstract] [Full Text] [Related]
20. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea. Ronnebaum S, Bron M, Patel D, Menno D, Bujanover S, Kratochvil D, Lucas E, Stepnowsky C. J Clin Sleep Med; 2021 Dec 01; 17(12):2543-2555. PubMed ID: 34402784 [Abstract] [Full Text] [Related] Page: [Next] [New Search]